Whitehawk Therapeutics
WHWK
53 hedge funds and large institutions have $47.2M invested in Whitehawk Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 16 reducing their positions, and 7 closing their positions.
309% more call options, than puts
Call options by funds: $94K | Put options by funds: $23K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
91% more capital invested
Capital invested by funds: $24.7M → $47.2M (+$22.5M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
12% more ownership
Funds ownership: 48.64% → 60.64% (+12%)
2% more funds holding
Funds holding: 52 → 53 (+1)
25% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$5.24M |
| 2 |
ABG
Ally Bridge Group
New York
|
+$1.85M |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$227K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$124K |
| 5 |
Two Sigma Investments
New York
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.4M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
-$904K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$96.9K |
| 4 |
Jane Street
New York
|
-$53.5K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $237 | -$14 | -6 | -7% |
|
|
PA
52
Parallel Advisors
San Francisco,
California
| $25 | – | – | – |
|
|
AI
53
Acuitas Investments
Seattle,
Washington
| – | -$904K | -438,760 | Closed |
|
|
AAA
54
Affinity Asset Advisors
New York
| – | -$96.9K | -47,019 | Closed |
|
|
55
Jane Street
New York
| – | -$53.5K | -25,989 | Closed |
|
|
GCP
56
GSA Capital Partners
London,
United Kingdom
| – | -$43K | -21,097 | Closed |
|
57
Squarepoint
New York
| – | -$21.7K | -10,510 | Closed |
|
|
CFM
58
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$8.45K | -4,100 | Closed |
|
59
Fidelity Investments
Boston,
Massachusetts
| – | -$5.36K | -2,600 | Closed |
|
WHWK Hedge Fund Activity: Q4 2024 in Review
53 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2024, worth a combined $47.2M — up 91% from $24.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new WHWK positions and 7 closed out — a net gain of 1 holder — while 12 added to existing stakes and 16 trimmed.
The largest buyer was QVT Financial, opening a new position worth an estimated $5.24M. The largest seller was EcoR1 Capital, cutting an estimated $3.4M.
- 53 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2024, up from 52 in Q3 2024.
- Funds reported $47.2M of Whitehawk Therapeutics stock for Q4 2024, up 91% quarter-over-quarter.
- 8 funds opened new Whitehawk Therapeutics positions in Q4 2024 and 7 closed out, a net change of +1 holder.
- The largest Whitehawk Therapeutics buyer in Q4 2024 was QVT Financial, an estimated $5.24M added.
- The largest Whitehawk Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2024.